https://www.selleckchem.com/pr....oducts/alkbh5-inhibi
Prevention of cardiovascular outcomes is a goal of the management of patients with type 2 diabetes mellitus patients as important as lowering blood glucose levels. Among the various glucose-lowering agents, the effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) and dipeptidyl peptidase-4 inhibitors (DPP-4Is) on cardiovascular outcomes have become the focus of recent researches. A systematic search was performed through several online database. All studies that compared the effects of SGLT-2Is and DPP-4Is on cardi
Like
Comment
Share
